Genetic Variation in the TP53 Gene and Patient Outcomes Following Severe Traumatic Brain Injury

Area of Science:

• Neuroscience
• Genetics
• Trauma Research

Background:

• Traumatic brain injury (TBI) is a significant cause of mortality and long-term disability.
• Over 5 million Americans live with TBI-related complications.
• The p53 protein's role in neuronal apoptosis after TBI necessitates investigating TP53 genetic variability.

Purpose of the Study:

• To examine the association between TP53 genetic variations and outcome variability in severe TBI patients.
• To determine if the TP53 Arg72Pro polymorphism can predict TBI outcomes.

Main Methods:

• A prospective study of 429 severe TBI patients (Glasgow Coma Scale score ≤8).
• Assessment of outcomes over 24 months, including mortality, Glasgow Outcome Scale (GOS), Neurobehavioral Rating Scale (NRS), and Disability Rating Scale (DRS).
• Investigation of the Arg72Pro (rs1042522) single-nucleotide polymorphism, focusing on the CC homozygous genotype.

Main Results:

• Individuals with the CC genotype (arginine homozygotes) exhibited significantly poorer outcomes at 24 months post-TBI.
• Poorer outcomes were observed in GOS (p = .048) and DRS (p = .022) for the CC genotype group.
• The CC genotype was associated with less efficient apoptosis induction.

Conclusions:

• TP53 genetic variability, specifically the Arg72Pro polymorphism, is linked to outcome variability after severe TBI.
• These findings support preliminary evidence of p53's role in TBI recovery.
• Further research could explore p53-based therapeutic strategies for TBI treatment.